News | Sexual health

News

NICE recommends cognitive behavioural therapy for treatment of menopause symptoms

The guidance says menopause-specific cognitive behavioural therapy can be used in addition to hormone replacement therapy or as an alternative.…

Published: 8 November 2024

News

NICE rejects cabotegravir for PrEP in draft guidance

Draft guidance said the HIV pre-exposure prophylaxis (PrEP) treatment cabotegravir is not recommended because “it is not possible to determine the cost-effectiveness estimate ... without further analyses from the manufacturer”.…

Published: 30 September 2024

News

Men taking valproate advised by MHRA to use effective contraception

The regulator advises that males and their partners should use effective contraception during, and for at least three months after, valproate treatment.…

Published: 9 September 2024

News

Pharmacies warned to be prepared to support people being released early from prison

NHS England has written to community pharmacy leads and GPs to request that they prepare to support people being released early from prison in September and October 2024.…

Published: 5 September 2024

News

Pharmacists risk being criminalised in puberty blockers ban, warns RPS

The Royal Pharmaceutical Society says the emergency prohibition order for gonadotrophin-releasing hormone may be leading to prescribers “unwittingly breaking the law”.…

Published: 1 August 2024

News

Government introduces ‘emergency ban’ on overseas prescriptions for puberty blockers

The new arrangements, which apply to gonadotropin-releasing hormone analogues, follow the Cass Review recommendation that inappropriate overseas prescribing of hormone supplies should be prevented.…

Published: 3 June 2024

Feature

Phosphodiesterase 5 receptor (PDE5) inhibitors similarities and differences: a non-prescription medicine perspective

Introduction Phosphodiesterase 5 receptor (PDE5) inhibitors have had a significant impact on the treatment of erectile dysfunction (ED), with the introduction of drugs like sildenafil citrate (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®). In 1998, Pfizer launched the first PDE…

Published: 3 April 2024

Pharmacists must be able to refer young people with gender dysphoria for support, says regulator

Duncan Rudkin, chief executive of the General Pharmaceutical Council, has warned that a lack of clear referral routes could lead people to seek alternative options, such as unregulated products or private clinics outside of the UK.…

Published: 21 March 2024

News

National pharmacy board meetings: February 2024

In the first national pharmacy board meetings of the year, each group discussed their plans and priorities for the year ahead.…

Published: 1 March 2024

News

Erectile dysfunction drugs may reduce Alzheimer’s risk, study suggests

Results from a study of more than 260,000 men has suggested those taking erectile dysfunction drugs were 18% less likely to develop Alzheimer's disease than those not taking the drugs.…

Published: 8 February 2024